<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To describe the clinical characteristics of human leukocyte antigen (HLA) B27 and B51 double-positive <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> and to determine whether the coexistence of HLA-B27 can affect <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We retrospectively reviewed the medical records of patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> and patients with HLA-B27-associated non-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> who underwent HLA-B27 and HLA-B51 typing and were followed up for more than 3 years </plain></SENT>
<SENT sid="2" pm="."><plain>We divided the patients into 3 groups according to HLA-B27/B51 status and compared the clinical outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>Main outcome measures were demographic features, <z:hpo ids='HP_0000554'>uveitis</z:hpo> characteristics, complications, treatments, and visual prognosis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Fourteen patients with HLA-B27(+)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo>, 43 patients with HLA-B27(-)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo>, and 41 patients with HLA-B27(+)B51(-) non-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> were identified </plain></SENT>
<SENT sid="5" pm="."><plain>HLA-B27(+)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> showed the demographic features similar to HLA-B27(-) counterparts </plain></SENT>
<SENT sid="6" pm="."><plain>However, HLA-B27(+)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> showed less involvement of posterior segments, a less <z:hpo ids='HP_0011010'>chronic</z:hpo> course, fewer complications in posterior segments, and less use of systemic medication or surgical intervention for inflammatory control, similar to HLA-B27(+)B51(-) non-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The long-term vision prognosis of HLA-B27(+)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> was more favorable than that of HLA-B27(-)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our results indicate that HLA-B27(+)B51(+) <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> is a benign subgroup of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The positivity of HLA-B27 may be a good prognostic factor in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
</text></document>